New Results
Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors
View ORCID ProfileMarc Hafner, Caitlin E. Mills, View ORCID ProfileKartik Subramanian, Chen Chen, Mirra Chung, View ORCID ProfileSarah A. Boswell, Robert A. Everley, Charlotte S. Walmsley, View ORCID ProfileDejan Juric, View ORCID ProfilePeter K. Sorger
doi: https://doi.org/10.1101/211680
Marc Hafner
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Caitlin E. Mills
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Kartik Subramanian
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Chen Chen
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Mirra Chung
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Sarah A. Boswell
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Robert A. Everley
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Charlotte S. Walmsley
2Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer, Center Boston, MA 02114
Dejan Juric
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
2Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer, Center Boston, MA 02114
Peter K. Sorger
1Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115
Posted November 07, 2017.
Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors
Marc Hafner, Caitlin E. Mills, Kartik Subramanian, Chen Chen, Mirra Chung, Sarah A. Boswell, Robert A. Everley, Charlotte S. Walmsley, Dejan Juric, Peter K. Sorger
bioRxiv 211680; doi: https://doi.org/10.1101/211680
Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors
Marc Hafner, Caitlin E. Mills, Kartik Subramanian, Chen Chen, Mirra Chung, Sarah A. Boswell, Robert A. Everley, Charlotte S. Walmsley, Dejan Juric, Peter K. Sorger
bioRxiv 211680; doi: https://doi.org/10.1101/211680
Subject Area
Subject Areas
- Biochemistry (11736)
- Bioengineering (8749)
- Bioinformatics (29186)
- Biophysics (14964)
- Cancer Biology (12086)
- Cell Biology (17403)
- Clinical Trials (138)
- Developmental Biology (9418)
- Ecology (14176)
- Epidemiology (2067)
- Evolutionary Biology (18299)
- Genetics (12235)
- Genomics (16795)
- Immunology (11863)
- Microbiology (28066)
- Molecular Biology (11582)
- Neuroscience (60936)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4956)
- Plant Biology (10423)
- Synthetic Biology (2883)
- Systems Biology (7338)
- Zoology (1650)